CLSD - Clearside Biomedical, Inc.
| Previous Close | 6.18 |
| Open | 6.21 |
| Bid | 6.37 x 2900 |
| Ask | 6.40 x 800 |
| Day's Range | 6.19 - 6.41 |
| 52 Week Range | 5.30 - 15.33 |
| Volume | 93,985 |
| Avg. Volume | 266,053 |
| Market Cap | 202.073M |
| Beta | -7.47 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.63 |
| Earnings Date | Nov 6, 2018 - Nov 12, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 23.00 |
- GlobeNewswire•7 days ago
Positive PEACHTREE Data to be Highlighted at EURETINA 2018
Clearside Biomedical, Inc. (CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that data from PEACHTREE, its pivotal Phase 3 trial of suprachoroidal CLS-TA in patients with macular edema associated with non-infectious uveitis, will be presented by Ron Neumann, MD, Uveitis Specialist at Maccabi Health Services, Tel Aviv, Israel and co-Chair of the International Symposium of Ocular Pharmacology and Therapeutics, during a Uveitis Free Paper session at the upcoming European Society of Retina Specialists (EURETINA) Congress 2018 in Vienna, Austria.
- Simply Wall St.•7 days ago
What Investors Should Know About Clearside Biomedical Inc’s (NASDAQ:CLSD) Financial Strength
Clearside Biomedical Inc (NASDAQ:CLSD) is a small-cap stock with a market capitalization of US$210.7m. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, theyRead More...
- GlobeNewswire•12 days ago
Data From Clearside Biomedical’s Pivotal Phase 3 PEACHTREE Clinical Trial in Macular Edema Associated with Non-Infectious Uveitis to be Presented at the Retina Society 51st Annual Scientific Meeting
ALPHARETTA, Ga., Sept. 13, 2018-- Clearside Biomedical, Inc., a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced ...
- GlobeNewswire•13 days ago
Clearside Biomedical Appoints Viral Kansara as Vice President, Discovery
Dr. Kansara brings over 12 years of experience and expertise in ophthalmic drug discovery, development and delivery to Clearside. Prior to joining Clearside, Dr. Kansara was Global Team Leader and Head of the Ocular Pharmacokinetic and Drug Delivery Lab in the Ophthalmology department at Novartis Institutes for Biomedical Research, Inc. At Novartis, Dr. Kansara’s lab focused on leveraging multiple modalities (biologics, small molecules, gene therapy and long-acting platforms) for the discovery and development of novel treatment therapies for blinding diseases such as age-related macular degeneration, diabetic retinopathy and glaucoma. Previously, he served as Senior Research Chemist, Pharm. Sciences and RNAi, at Merck & Co., Inc. and also completed a Graduate Research Collaboration with Alcon Research Ltd., focused on the delivery of therapies to the back of the eye. Dr. Kansara earned his Ph.D. in the field of Pharmaceutical Sciences from the University of Missouri-Kansas City and has authored two book chapters and numerous research articles.
- GlobeNewswire•14 days ago
Clearside Biomedical Appoints Accomplished Pharmaceutical Industry Legal Executive, Leslie Zacks, as General Counsel and Chief Compliance Officer
Clearside Biomedical, Inc. (CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced the appointment of Leslie Zacks as General Counsel and Chief Compliance Officer.
- GlobeNewswire•15 days ago
Clearside Biomedical to Participate in 2018 Janney Healthcare Conference
Clearside Biomedical, Inc. (CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that its Chief Executive Officer and President, Daniel H. White, will present at the 2018 Janney Healthcare Conference on Monday, September 17, 2018 at 11:35 a.m. ET at the Union League Club in New York, NY. A live webcast of the presentation can be accessed on the company’s website at www.clearsidebio.com under the “Events & Presentations” tab in the “Investor Relations” section. Following the conference, the presentation webcast will be archived on the website for 30 days.
- GlobeNewswire•19 days ago
Clearside Biomedical Further Strengthens Commercial Organization With Appointment of Lester Rodríguez as Vice President, Quality
Clearside Biomedical, Inc. (CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced the appointment of Lester Rodríguez as Vice President, Quality. As Clearside prepares to transition from a clinical-stage to a commercial-stage company, Mr. Rodríguez will be responsible for ensuring that the company continues to design and implement appropriate programs, policies and procedures related to quality assurance and quality control activities across the company and its suppliers. He will also provide cross-functional compliance oversight of activities involving all recognized quality standards for the pharmaceutical industry, such as good manufacturing practices and good clinical practices.
- GlobeNewswire•last month
Analysis: Positioning to Benefit within Armstrong Flooring, U.S. Global Investors, Aqua Metals, Clearside Biomedical, EP Energy, and Avadel Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Aug. 17, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Armstrong ...
- GlobeNewswire•2 months ago
Clearside Biomedical to Participate in 2018 Wedbush PacGrow Healthcare Conference
Clearside Biomedical, Inc. (CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that its Chief Executive Officer and President, Daniel H. White, will present at the 2018 Wedbush PacGrow Healthcare Conference on Wednesday, August 15, 2018 at 8:35 a.m. ET at the Parker New York. Follow @clearsidebio on Twitter and Linkedin.
- GlobeNewswire•2 months ago
Clearside Biomedical Announces Second Quarter 2018 Financial Results and Provides Corporate Update
Clearside Biomedical, Inc. (CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today reported financial results for the quarter ended June 30, 2018 and provided an update on its development programs. “We remain on track to submit our first NDA before the end of this year and are continuing to make significant progress in advancing our late-stage pipeline,” said Daniel H. White, Chief Executive Officer and President of Clearside. Suprachoroidal CLS-TA, Clearside’s first investigational treatment program, is a proprietary suspension of the corticosteroid triamcinolone acetonide formulated for administration to the back of the eye via the suprachoroidal space, or SCS®, which is the space located between the choroid and the outer protective layer of the eye known as the sclera.
- ACCESSWIRE•2 months ago
Clearside Biomedical, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Clearside Biomedical, Inc. (NASDAQ: CLSD ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 8:30:00 AM Eastern ...
- GlobeNewswire•2 months ago
Clearside Biomedical to Report Second Quarter 2018 Financial Results on August 8, 2018 – Conference Call to Follow
Clearside Biomedical, Inc. (CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that its second quarter 2018 financial results will be released at approximately 7:00 a.m. ET on Wednesday, August 8, 2018. Following the release, Clearside will host a live conference call and webcast at 8:30 a.m. ET to discuss its financial results and provide a general business and strategic review. The live webcast and a replay may be accessed by visiting the “Investor Relations” section at www.clearsidebio.com. Alternately, please call (844) 263-8310 (U.S.) or (213) 358-0959 (international) to participate in the live conference call. The conference ID number for the live call is 6390517. Please dial in approximately 10 minutes prior to the call. An archive of the webcast will be available until September 8, 2018.
- GlobeNewswire•2 months ago
Clearside Biomedical to Present Data from its Pivotal Phase 3 (“PEACHTREE”) Trial in Macular Edema Associated with Uveitis at the 2018 American Society of Retina Specialists Annual Meeting
Clearside Biomedical, Inc. (“Clearside”), (CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that data from PEACHTREE, its pivotal Phase 3 trial of suprachoroidal CLS-TA in patients with macular edema associated with non-infectious uveitis, will be shared as a late-breaking oral presentation during the 2018 annual meeting of the American Society of Retina Specialists (“ASRS”), (#asrs2018), July 20-25 in Vancouver, Canada. The company will host a Medical Affairs booth (#309) at the ASRS meeting. Positive top-line results from the PEACHTREE trial were announced in March 2018.
- GlobeNewswire•2 months ago
Clearside Biomedical Appoints Carol Hoang as Vice President, Medical Affairs
Clearside Biomedical, Inc. (CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced the appointment of Carol Hoang, Pharm.D., MBA, to the position of Vice President, Medical Affairs.
- ACCESSWIRE•3 months ago
Free Technical Research on Clovis Oncology and Three More Biotech Equities
LONDON, UK / ACCESSWIRE / July 6, 2018 / If you want a free Stock Review on CLVS sign up now at www.wallstequities.com/registration. On Thursday, July 05, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. All sectors ended Thursday's trading session in bullish territories.
- ACCESSWIRE•4 months ago
Blog Exposure - Clearside Reports Encouraging Data from Phase-2 Trial of CLS-TA Used with Eylea in Patients with Diabetic Macular Edema
LONDON, UK / ACCESSWIRE / June 4, 2018 / If you want access to our free research report on Clearside Biomedical, Inc. (NASDAQ: CLSD) ("Clearside"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=CLSD as the Company's latest news hit the wire. On May 31, 2018, the Company announced positive top-line results from its Phase-2 clinical trial, TYBEE, evaluating suprachoroidal CLS-TA used with intravitreally-administered EYLEA® (aflibercept) in patients with diabetic macular edema (DME) over a 6-month evaluation period.
- Zacks•4 months ago
Options Traders Expect Huge Moves in Clearside Biomedical (CLSD) Stock
Clearside Biomedical (CLSD) needs investors to pay close attention to the stock based on moves in the options market lately.
- ACCESSWIRE•4 months ago
Today’s Research Reports on Stocks to Watch: Kitov Pharma and Clearside Biomedical
NEW YORK, NY / ACCESSWIRE / June 1, 2018 / It was FDA news that sent shares of Kitov Pharma blasting off on Thursday. Shares of Clearside Biomedical sunk despite positive topline results being announced ...
- Motley Fool•4 months ago
Clearside Biomedical Stock Down 26%: The "Positive" Data That Wasn't
Sometimes press release headlines and share prices don't match up.
- TheStreet.com•5 months ago
Markets Make an Art of Unpredictability
The market is doing a nice job of being unpredictable with a sudden intraday spike on no obvious news. Strength in oil is receiving most of the credit for the overall market strength today but it is likely that there are some buy programs triggered now that the S&P500 has moved over the 50-day moving average at 2672 and has held. Bears were looking for the maket to stall out as it hit the top of the recent trading range that goes back to March 22, but they are now being squeezed as the market shrugs off the Iran news and doesn't seem to need any obvious positive news catalyst to keep on running.
